Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Oncology
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Oncology
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Pharma
Unapproved in US for decades, levosimendan stumbles in ph. 3
Despite the flop, Tenax has zeroed in on a prespecified subgroup of patients with greater disease burden and plans to request a meeting with the FDA.
Angus Liu
Aug 10, 2026 4:40pm
Abbott taps telenovela star to take the drama out of cancer test
Aug 10, 2026 1:47pm
Designing an agentic, future‑ready tech roadmap for emerging pharma
Brought to you by
ZS
Novo’s Catalent plant ditched in FDA refiling of SMA drug
Aug 10, 2026 10:06am
Pharma marketers face privacy hurdles, turn to omnichannel strategies
Brought to you by
Swoop
Eli Lilly's Zepbound preferred by physicians: Spherix survey
Aug 7, 2026 11:36am
